389results about How to "Achieve early diagnosis" patented technology

The invention discloses a short circuit fault self-detection method in a single battery. The method comprises the following steps of: S1, building a first-order equivalent circuit model of the battery, determining a function relation between a state of charge (SOC) and an open-circuit voltage (OCV), and recognizing model parameters, S2, measuring load current and terminal voltage of the battery inreal time, S3, calculating ampere-hour increments at adjacent moments, estimating the SOC of the battery online by adopting a closed-loop state observer, and calculating an internal short circuit current according to the obtained ampere-hour increments and an SOC change value, S4, filtering the estimated internal short circuit current, and identifying the internal short circuit resistance of thebattery online by adopting a recursive least square method with an adaptive forgetting factor according to the filtered internal short circuit current and load voltage. According to a preset internalshort circuit resistance threshold, the internal short circuit state of the battery is compare3d and judged. Online identification of the short circuit resistance in the single battery can be realizedonly by measuring the terminal voltage and the load current of the single battery, and other single battery information in the battery pack is not needed.

The invention discloses application of MYOZ1 in diagnosing and treating parkinsonism, belonging to the technical field of new application of genes. The experiment proves that the MYOZ1 gene expression in the blood of a parkinsonism patient is enhanced as compared with a normal person, which indicates that the MYOZ1 expression level in the blood can be detected to diagnose whether a subject suffers from parkinsonism. The in-vitro MTT experiment detect that the MYOZ1 gene expression is not beneficial to growth of human neuroblastoma cells. Therefore, the MYOZ1 has favorable development and application prospects in preparing products for diagnosing and treating parkinsonism.

The invention relates to a polypeptide immunoassay kit, which comprises a protein G or protein A agarose serving as a solid phase carrier, a purified serum polypeptide antibody and PBS buffer solution. The invention also relates to a polypeptide immunomic spectrometry analysis method, which comprises the following steps: coupling a purified serum antibody with a proper solid carrier; allowing the coupled product to bond with a polypeptide marker antigen specifically, and separating the antigen from the carrier by using eluent; and finally, detecting polypeptide antigen in the eluent by high-pass matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOFMS). Thus, the complete immunomic spectrometry analysis method is established.

The invention relates to a fire detection, prevention and control system of an electronic control cabinet. The fire detection, prevention and control system comprises a data acquisition device, a fire extinguishing device and a main control device which are arranged in an electronic control cabinet body, wherein the data acquisition device is used for acquiring detection data of each detection node in the electronic control cabinet in real time, and transmitting the detection data to the main control device; the fire extinguishing device is used for accepting a control signal sent by the main control device, and carrying out fire control and processing on an area with a fire early warning; a fire extinguishing control module is used for sending a control signal to the fire extinguishing device according to the instruction of a CPU (central processing unit) core module. The invention further discloses a control method based on the system. The control method comprises the following steps: transmitting the CO and smoke concentration acquired in real time to the CPU core module; processing by a pre-detection data filter model to obtain a characteristic extraction value; if fire early warning standards are met, sending an early warning or starting the fire extinguishing device. The fire detection, prevention and control system and the control method disclosed by the invention are capable of performing real-time detection on a small space such as the electronic control cabinet, eliminating fire in the bud, and reducing the false alarm rate of fire early warning.

The invention provides a human papillomavirus HPV DNA fragment, a mix primer for human papillomavirus HPV DNA detection and/ or parting and application thereof. The mixed primer can specifically amplify to obtain one or a plurality of DNA sequences from HPV6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 39, HPV 40, HPV 42, HPV 43, HPV 44, HPV45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 66, HPV 68, HPV 70, HPV 72, HPV 73, HPV 81, HPV 82 and HPV 83, can be used for the human papillomavirus HPV DNA detection and/ or parting and prepared into a PCR kit. The invention can detect common types of HPV at a time, greatly improve the HPV detection efficiency, overcome the defect of missed detection of latent infection by a serology and IHC detection method, realize early diagnosis of HPV diseases, and is suitable for clinical HPV gene detection and parting and guides prevention and cure of cervical carcinoma.

The invention discloses a gene BPIFB1 and an expression product thereof. The gene BPIFB1 is a molecular marker for tongue squamous cell carcinoma early diagnosis. The gene BPIFB1 and the expression product have the advantages that as proved by QPCR (quantitative polymerase chain reaction), the gene BPIFB1 can be differently expressed in tongue squamous cell carcinoma tissues and para-carcinoma tissues and can be used as an indicator for tongue squamous cell carcinoma early diagnosis; the gene BPIFB1 and the expression product can be used as targets for treating tongue squamous cell carcinoma and can be used for guiding research and development of new medicines.

The invention discloses an LYPD3 gene and an expression product thereof both of which can serve as molecular markers for diagnosing osteoporosis. According to the LYPD3 and the expression product disclosed by the invention, a QPCR (quantitative polymerase chain reaction) experiment and a Western blot experiment provide that the LYPD3 gene has expression difference in blood or bone tissues of a normal person and an osteoporosis patient and can be used as an index for early diagnosis of the osteoporosis. In addition, the invention also discloses the LYPD3 gene and the expression product thereof both of which can serve as targets for diagnosing the osteoporosis and be used for guiding the research and development of novel medicaments.

The invention discloses PLAC1 (placenta-specific 1) genes which can serve as a molecular marker for early diagnosis of osteoarthritis. Expressions of the PLAC1 genes in synovial tissue of a normal person and a patient suffering from osteoarthritis prove to be different in terms of the transcriptional level and the protein level, and accordingly, the disease risk and the disease state of a subject can be judged according to the identified expression level of the PLAC1 genes. Additionally, experiments prove that interference to expression of the PLAC1 genes or inhibition on the function of PLAC protein can inhibit proliferation of synovial cells, and a new target is provided for development of medicines for treating osteoarthritis clinically.

The invention discloses an osterarthritis diagnosis marker which refers to MTUSI gene and expression products thereof. According to gene chip and protein immunization tests, expressions of the MTUSI gene and expression products thereof are lowered in blood and bone tissue of osterarthritis patients as compared with those of the normal; thus, products for diagnosis of osterarthritis can be developed and can be applied to testing expression level of the MTUSI gene or expression products thereof. According to experiment in vitro, bone cell proliferation can be improved by over-expression of the MTUSI gene, and accordingly the MTUSI gene and the expression products thereof can be applied to development of medicines for treating osterarthritis.

A process for earlierly detecting pine nematosis includes inoculating the disc fungus (Ps0202) or other microbial fungi on culture medium, drilling circular hole on the pine trunk to be detected, inserting the test tube containing said fungi in said hole, staying it in the hole for 3-5 days, and determining by microscope. Its advantages are easy operation and high sensitivity.

The invention provides recombined II-type herpes simplex virus. In the virus, ICP34.5 gene of a wild II-type herpes simplex virus HG52 strain is excluded, and a fluorescent protein expression box is inserted in the gene group. The invention also provides a preparation method of the recombined II-type herpes simplex virus, the application of the recombined II-type herpes simplex virus in preparation of the drug for diagnosing tumours, and a tumour diagnostic reagent kit with the recombined II-type herpes simplex virus. In the recombined II-type herpes simplex virus disclosed by the invention, the ICP34.5 gene is excluded, so that the recombined II-type herpes simplex virus can selectively grow and breed in tumour cells, the recombined II-type herpes simplex virus is inserted in the fluorescent protein expression box and can give out fluorescence in tumour cells, so that the tumour diagnostic reagent kit with the recombined II-type herpes simplex virus can quickly, accurately, sensitively and broadly detect whether a sample to be detected contains tumour cells or not.

The invention provides a diagnostic kit for detecting active pulmonary tuberculosis. The kit consists of an RNA extract buffer solution, a specific serum miRNA composition for the active pulmonary tuberculosis, internal reference reverse transcription primers, polymerase chain reaction (PCR) primers and a fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR) reaction solution, wherein the specific serum miRNA composition for the active pulmonary tuberculosis consists of four differential expression serum miRNAs, namely hsa-miR-29c, hsa-miR-22, hsa-miR-320b and hsa-miR-101. By using the specific serum miRNAs composition for the active pulmonary tuberculosis to detect the active pulmonary tuberculosis on the serum miRNAs level, the sensitivity is 90.2 percent, and the specificity is 75.0 percent; and the kit has early-stage diagnostic value for the active pulmonary tuberculosis, and can realize early warning and early diagnosis of the active pulmonary tuberculosis.

The invention discloses an application of miR-3613 as a miRNA marker in distinguishing metastasis and non-metastasis of lung squamous carcinoma. Accordingly, the miR-3613 can be used for developing products for diagnosing lung squamous carcinoma metastasis and drugs for treating lung squamous carcinoma metastasis. The research result of the invention provides a theoretical basis for making individual-based treatment schemes by clinical physicians and can provide a new drug target for developing lung squamous carcinoma drugs.